Announcements Trials
Browse Landscape

Phase

Phase 1/2 2

Status

Terminated 1Recruiting 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2Genitourinary 2Dermatologic 2Breast 2Thoracic 1Other solid neoplasm 1Head & Neck 1Gastrointestinal 1

Conditions

Melanoma 105Carcinoma, Renal Cell 38Leukemia, Myeloid, Acute 36Neoplasm Metastasis 31Neoplasms 22Breast Neoplasms 22Lymphoma, Non-Hodgkin 21Kidney Neoplasms 20Leukemia 18Carcinoma, Non-Small-Cell Lung 18Skin Neoplasms 17Neuroblastoma 17Ovarian Neoplasms 16Colorectal Neoplasms 16Recurrence 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lymphoma 13Myelodysplastic Syndromes 10Uveal Melanoma 9Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Lymphoma, Follicular 9Head and Neck Neoplasms 9Uterine Cervical Neoplasms 8Multiple Myeloma 8Congenital Abnormalities 8Triple Negative Breast Neoplasms 7Stomach Neoplasms 7Lung Neoplasms 7Hodgkin Disease 7Squamous Cell Carcinoma of Head and Neck 6

Interventions

Gemcitabine 157Cisplatin 117pembrolizumab 81Cystectomy 46Nivolumab 42Carboplatin 42Paclitaxel 41Mitomycin 41Docetaxel 39atezolizumab 33Magnetic Resonance Spectroscopy 33Radiotherapy 31durvalumab 30avelumab 26BCG Vaccine 26Specimen Handling 25Cystoscopy 24enfortumab vedotin 23Doxorubicin 23Fluorouracil 20Methotrexate 17Vinblastine 16Standard of Care 15Ipilimumab 14Filgrastim 145-aminolevulinic acid hexyl ester 14Transurethral Resection of Bladder 13Surgical Procedures, Operative 13Sunitinib 13Biopsy 13

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Urinary Bladder Neoplasms × Interleukin-2 × Clear all
NCT05086692 2025-07-09

ABILITY-1

Medicenna Therapeutics, Inc.

Phase 1/2 Recruiting
115 enrolled
BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmThoracic

Turcot syndrome, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Mesothelioma, Malignant, Urinary Bladder Neoplasms, Carcinoma, Basal Cell, Carcinoma, Renal Cell, Uterine Cervical Neoplasms, Esophageal Neoplasms, Fallopian Tube Neoplasms, Melanoma, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Carcinoma, Merkel Cell, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT02153905 2019-06-17

T Cell Receptor Immunotherapy Targeting MAGE-A3 for Patients With Metastatic Cancer Who Are HLA-A*01 Positive

National Institutes of Health Clinical Center (CC)

Phase 1/2 Terminated
3 enrolled 14 charts
BreastDermatologicGenitourinaryGynecologic

Urinary Bladder Neoplasms, Breast Neoplasms, Uterine Cervical Neoplasms, Kidney Neoplasms, Melanoma, Neoplasm Metastasis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡